Research presented at the Society for Behavioral Medicine’s Annual Meeting furthers Omada’s robust body of evidence, highlighting the potential of personalized care paths to improve program engagement and health outcomes.

Omada Health, the virtual between-visit healthcare provider, announced new data were presented at the Society for Behavioral Medicine’s (SBM) Annual Meeting from March 26-29, 2025 in San Francisco. Findings showcased the impact of Omada’s cardiometabolic programs, including GLP-1 and prevention-specific programs, on member engagement and health outcomes.

As part of its commitment to developing programs supported by real-world clinical evidence, Omada has conducted several analyses to examine its hypothesis that care tailored to specific patient needs can improve engagement and outcomes for members. Data from two analyses with unique populations showed that:

Health Technology Insights: Dupixent Approved as First Biologic for COPD in Japan

Virtual care members who had the opportunity to choose their learning paths engaged with the program more, on average, than those not given the option to choose.

  • Members of the Omada for Prevention program who indicated managing food cravings as a barrier to engaging in healthy lifestyle behaviors were offered “learning paths” of focused content.
  • These participants saw an increase in meaningful engagement with the program compared to similar participants who did not have the option to choose their “learning paths,” suggesting that empowering members to choose guided pathways can increase the uptake of health behavior change strategies.
  • Read the full abstract on Omada’s website.

Members in Omada’s Enhanced GLP-1 Care Track were more engaged with the program and experienced more weight loss, on average, than those not receiving GLP-1 specific support.

  • The analysis compared Omada members who had recently started using GLP-1s for weight loss and participated in Omada’s Enhanced GLP-1 Care Track to those using a GLP-1 for weight loss in the Omada for Prevention and Hypertension standard programs.
  • Omada’s Enhanced GLP-1 Care Track, announced in 2024, was designed to support members throughout GLP-1 use and afterward leveraging behavioral support, weight monitoring, nutrition, medication management education, and tailored exercise and movement plans to optimize outcomes.
  • Early results through 16 weeks for members in the Enhanced GLP-1 Care Track demonstrated a 28% greater average weight loss, 27% more self-reported days physically active on average, and a 22% greater average overall engagement with the program. Additional data from this sample of members was also published late last year.
  • Read the full abstract on Omada’s website.

“These data serve as a crucial reminder that effective digital health programs must go beyond a one-size-fits-all approach,” said Ellen Beckjord, PhD, MPH, President of the Society of Behavioral Medicines, Vice President of Population Health and Clinical Optimization at UPMC Health Plan and a member of the Omada Health Clinical Advisory Board. “By leveraging evidence-based strategies to provide personalized support, we can empower individuals to improve their health—and ultimately improve population health outcomes.”

An additional abstract presented at SBM’s Annual Meeting highlighted the relationship between chronic diseases and mental health, demonstrating the importance of behavioral health tools in chronic care management. Participants who were enrolled in Omada Health’s cardiometabolic programs experienced improvements in clinical measures of depression and anxiety symptoms.

  • Members enrolled inOmada’s cardiometabolic programs, which include integrated behavioral health tools, were evaluated over 16 weeks.
  • Participants demonstrated a meaningful improvement in average PHQ-4 scores over 16 weeks, and those with elevated depression and anxiety symptoms had a 3.2-point average improvement in PHQ-4 scores. These findings were significant across diverse sociodemographic populations.
  • Improving mental health may help reduce cardiometabolic disease development and complications.
  • Read the full abstract on Omada’s website.

Health Technology Insights: Europe-Wide Launch of Interventional Ultrasonic Endoscope

“Clinical measures like weight loss are valuable to help us understand program success, but they don’t tell the whole story of member health,” said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research, Omada Health. “These findings demonstrate how important it is to examine a broad range of outcomes to truly understand how far-reaching the positive impact of virtual care programs, like Omada, can be for chronic care management.”

These analyses were conducted through Omada’s Insights Lab, which builds on more than a decade of insights and 29 peer-reviewed publications assessing the efficacy of behavior change programs to improve chronic disease management.

Health Technology Insights: Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients 

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – businesswire